International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
The utility of the novel biomarker HE4 for monitoring epithelial ovarian cancer during PARP inhibitor treatment.
Alexandra Morell, Anne Stoklosa, Alexandra Blackman, Youngeun Armbuster, Rachael Rowswell-Turner, M Craig Miller, Richard G Moore
Published: 202510.1016/j.ijgc.2025.102682
Abstract
OBJECTIVE: Poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is commonly used in patients with ovarian cancer. Prior studies have reported that serum cancer antigen 125 (CA125) poorly predicts disease progression for patients on PARP i…
Preview only. Read the full abstract at the source